Gt biopharma announces sponsored research agreement with dr. jeffrey s. miller of the university of minnesota

Deepening relationship between gt biopharma and dr. jeffrey miller trike™ improves ft538 ipsc nk cells from fate therapeutics in prostate cancer model gtb-3550 continues to demonstrate clinical success without significant toxicities beverly hills, calif., july 7, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary nk cell engager (trike™) protein biologic technology platform, announced it has entered into a sponsored research agreement (sra) with jeffrey s.
GTBP Ratings Summary
GTBP Quant Ranking